TRACON Pharmaceuticals Provides Update on Phase 1/2 Trial of TRC253 in Patients with Metastatic Castrate Resistant Prostate Cancer
TRACON PHARMS INC (TCON)
Last tracon pharms inc earnings: 2/27 04:03 pm
Check Earnings Report
US:NASDAQ Investor Relations:
traconpharma.com
Company Research
Source: GlobeNewswire
Phase 1 Data Published in ASCO Proceedings Determined the Recommended Phase 2 Dose Additional Cohort of Patients with a Specific Androgen Receptor Point Mutation Added to Ongoing Phase 2 Study Phase 2 Data Expected in 2nd half 2020; Potential for $45 Million Opt-in Payment from Janssen SAN DIEGO, July 02, 2019 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related macular degeneration through our license to Santen Pharmaceutical Co. Ltd., and utilizing our product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today provided an update on its TRC253 program for the treatment of metastatic castrate resistant prostate cancer, which was licensed from Janssen Pharmaceutica N.V. in 2016. Phase 1 data from the ongoing Phase 1/2 clinical trial published in th
Show less
Read more
Impact Snapshot
Event Time:
TCON
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TCON alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TCON alerts
High impacting TRACON PHARMS INC news events
Weekly update
A roundup of the hottest topics
TCON
News
- TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- TRACON Pharmaceuticals, Inc. (NASDAQ: TCON) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
TCON
Earnings
- 5/14/24 - Miss
TCON
Sec Filings
- 11/7/24 - Form 15-12G
- 11/4/24 - Form EFFECT
- 11/4/24 - Form EFFECT
- TCON's page on the SEC website